Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tango Therapeutics (TNGX) EPS (Basic) (2020 - 2025)

Tango Therapeutics has reported EPS (Basic) over the past 6 years, most recently at -$0.3 for Q4 2025.

  • Quarterly results put EPS (Basic) at -$0.3 for Q4 2025, up 11.76% from a year ago — trailing twelve months through Dec 2025 was -$0.87 (up 27.5% YoY), and the annual figure for FY2025 was -$0.87, up 26.89%.
  • EPS (Basic) for Q4 2025 was -$0.3 at Tango Therapeutics, down from $0.14 in the prior quarter.
  • Over the last five years, EPS (Basic) for TNGX hit a ceiling of $0.14 in Q3 2025 and a floor of -$0.36 in Q1 2025.
  • Median EPS (Basic) over the past 5 years was -$0.29 (2021), compared with a mean of -$0.26.
  • Biggest five-year swings in EPS (Basic): plummeted 68424.89% in 2021 and later surged 151.85% in 2025.
  • Tango Therapeutics' EPS (Basic) stood at -$0.26 in 2021, then dropped by 26.92% to -$0.33 in 2022, then grew by 9.09% to -$0.3 in 2023, then dropped by 13.33% to -$0.34 in 2024, then rose by 11.76% to -$0.3 in 2025.
  • The last three reported values for EPS (Basic) were -$0.3 (Q4 2025), $0.14 (Q3 2025), and -$0.35 (Q2 2025) per Business Quant data.